Kåre Schultz, Teva CEO (Christopher Goodney/Bloomberg via Getty Images)

Te­va suf­fers set­back on in-house asth­ma pro­gram as a PhII study is halt­ed ear­ly due to fu­til­i­ty

Al­though Te­va large­ly makes its mon­ey these days through gener­ic drug sales, the com­pa­ny con­tin­ues to de­vel­op a suite of asth­ma med­i­cines and in­halers for its in-house R&D ef­forts. But one such can­di­date has ap­par­ent­ly hit a speed bump.

Ac­cord­ing to a Mon­day up­date post­ed on clin­i­cal­tri­als.gov, Te­va ter­mi­nat­ed a Phase II asth­ma study ear­ly due to fu­til­i­ty fol­low­ing an in­ter­im analy­sis. The tri­al had been look­ing to eval­u­ate the pro­gram known as TEV-48574 in 65 adults over 16 weeks, re­gard­less if their se­vere asth­ma is trig­gered by al­ler­gens.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.